SRPT: Summary for Sarepta Therapeutics, Inc. - Yahoo Finance

UK Markets closed

Sarepta Therapeutics, Inc. (SRPT)


NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
36.18+1.46 (+4.21%)
As of 1:45PM EDT. Market open.
People also watch
ACADCLVSPTCTCLDXICPT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close34.72
Open38.00
Bid35.53 x 400
Ask35.58 x 100
Day's range35.29 - 39.34
52-week range13.70 - 63.73
Volume7,529,812
Avg. volume2,204,996
Market cap1.98B
Beta2.05
PE ratio (TTM)-6.59
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • American City Business Journals3 hours ago

    ​Sarepta shares jump as CEO’s planned exit spurs takeover speculation

    Shares of Sarepta Therapeutics soared Friday morning amid speculation that the planned departure of CEO Ed Kaye makes the Cambridge biotech a prime takeover target. Kaye made the surprise announcement on a conference call with analysts Thursday, saying that he will step down from his role as CEO of Sarepta (SRPT) by the end of the year, but will remain on the company’s board. Meanwhile, TheStreet’s Adam Feuerstein speculated Friday that Sanofi (SNY) could emerge as a suitor.

  • Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up
    Zacks3 hours ago

    Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

    Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased

  • Barrons.com3 hours ago

    Yes, Sarepta Reported Earnings…But That's Not Why It's Flying Today

    Sarepta Therapeutics (SRPT) reported a larger-than-expected loss but much better sales this morning, which had given its shares a small boost in pre-open trading. Speculation that Sarepta could be taken over, however, have caused its shares to skyrocket. Sarepta stated its prescriber base increased 30% from 4Q16 (30 physicians submitting forms) and all tier 1 centers having submitted start forms, and first start forms from tier 3 centers have begun to flow in.